nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—Diphenidol—Benzphetamine—obesity	0.453	1	CrCrCtD
Trihexyphenidyl—Urinary hesitation—Phenylpropanolamine—obesity	0.0128	0.042	CcSEcCtD
Trihexyphenidyl—Sinus bradycardia—Cimetidine—obesity	0.00848	0.0278	CcSEcCtD
Trihexyphenidyl—Angle closure glaucoma—Bupropion—obesity	0.00719	0.0236	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Methamphetamine—obesity	0.00601	0.0197	CcSEcCtD
Trihexyphenidyl—Mydriasis—Diethylpropion—obesity	0.00548	0.018	CcSEcCtD
Trihexyphenidyl—Intraocular pressure increased—Sibutramine—obesity	0.00505	0.0166	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Methamphetamine—obesity	0.00496	0.0163	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Benzphetamine—obesity	0.00478	0.0157	CcSEcCtD
Trihexyphenidyl—Cognitive impairment—Topiramate—obesity	0.00473	0.0155	CcSEcCtD
Trihexyphenidyl—Angle closure glaucoma—Topiramate—obesity	0.00458	0.015	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Phenylpropanolamine—obesity	0.00451	0.0148	CcSEcCtD
Trihexyphenidyl—Intraocular pressure increased—Bupropion—obesity	0.0044	0.0145	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Phendimetrazine—obesity	0.00436	0.0143	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Phentermine—obesity	0.00432	0.0142	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Diethylpropion—obesity	0.00375	0.0123	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Phenylpropanolamine—obesity	0.00372	0.0122	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Phentermine—obesity	0.00356	0.0117	CcSEcCtD
Trihexyphenidyl—Delusion—Sibutramine—obesity	0.00314	0.0103	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Diethylpropion—obesity	0.0031	0.0102	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Cimetidine—obesity	0.00295	0.00968	CcSEcCtD
Trihexyphenidyl—Drowsiness—Phenylpropanolamine—obesity	0.00294	0.00964	CcSEcCtD
Trihexyphenidyl—Cognitive disorder—Topiramate—obesity	0.00285	0.00937	CcSEcCtD
Trihexyphenidyl—Paranoia—Bupropion—obesity	0.00284	0.00933	CcSEcCtD
Trihexyphenidyl—Agitation—Methamphetamine—obesity	0.00281	0.00922	CcSEcCtD
Trihexyphenidyl—Intraocular pressure increased—Topiramate—obesity	0.00281	0.00921	CcSEcCtD
Trihexyphenidyl—Delusion—Bupropion—obesity	0.00274	0.00898	CcSEcCtD
Trihexyphenidyl—Agitation—Benzphetamine—obesity	0.00271	0.00889	CcSEcCtD
Trihexyphenidyl—Hallucination—Phenylpropanolamine—obesity	0.00262	0.00861	CcSEcCtD
Trihexyphenidyl—Vision blurred—Phendimetrazine—obesity	0.00253	0.00831	CcSEcCtD
Trihexyphenidyl—Sinus bradycardia—Topiramate—obesity	0.00252	0.00826	CcSEcCtD
Trihexyphenidyl—Hallucination—Phentermine—obesity	0.00251	0.00824	CcSEcCtD
Trihexyphenidyl—Agitation—Phendimetrazine—obesity	0.00247	0.0081	CcSEcCtD
Trihexyphenidyl—Memory impairment—Bupropion—obesity	0.00247	0.0081	CcSEcCtD
Trihexyphenidyl—Drowsiness—Diethylpropion—obesity	0.00244	0.00802	CcSEcCtD
Trihexyphenidyl—Tachycardia—Methamphetamine—obesity	0.00243	0.00799	CcSEcCtD
Trihexyphenidyl—Mydriasis—Bupropion—obesity	0.00243	0.00797	CcSEcCtD
Trihexyphenidyl—Tachycardia—Benzphetamine—obesity	0.00235	0.00771	CcSEcCtD
Trihexyphenidyl—Drowsiness—Cimetidine—obesity	0.00233	0.00764	CcSEcCtD
Trihexyphenidyl—Tension—Phenylpropanolamine—obesity	0.00225	0.00739	CcSEcCtD
Trihexyphenidyl—Nervousness—Phenylpropanolamine—obesity	0.00223	0.00732	CcSEcCtD
Trihexyphenidyl—Vision blurred—Phenylpropanolamine—obesity	0.00216	0.0071	CcSEcCtD
Trihexyphenidyl—Tension—Phentermine—obesity	0.00215	0.00707	CcSEcCtD
Trihexyphenidyl—Accommodation disorder—Topiramate—obesity	0.00215	0.00705	CcSEcCtD
Trihexyphenidyl—Tachycardia—Phendimetrazine—obesity	0.00214	0.00702	CcSEcCtD
Trihexyphenidyl—Constipation—Methamphetamine—obesity	0.00213	0.007	CcSEcCtD
Trihexyphenidyl—Nervousness—Phentermine—obesity	0.00213	0.007	CcSEcCtD
Trihexyphenidyl—Agitation—Phenylpropanolamine—obesity	0.00211	0.00692	CcSEcCtD
Trihexyphenidyl—Hallucination—Cimetidine—obesity	0.00208	0.00682	CcSEcCtD
Trihexyphenidyl—Agitation—Phentermine—obesity	0.00202	0.00662	CcSEcCtD
Trihexyphenidyl—Hyperkinesia—Sibutramine—obesity	0.00194	0.00636	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Sibutramine—obesity	0.00191	0.00627	CcSEcCtD
Trihexyphenidyl—Confusional state—Phenylpropanolamine—obesity	0.00189	0.0062	CcSEcCtD
Trihexyphenidyl—Constipation—Phendimetrazine—obesity	0.00187	0.00615	CcSEcCtD
Trihexyphenidyl—Tension—Diethylpropion—obesity	0.00187	0.00615	CcSEcCtD
Trihexyphenidyl—Nervousness—Diethylpropion—obesity	0.00186	0.00609	CcSEcCtD
Trihexyphenidyl—Tachycardia—Phenylpropanolamine—obesity	0.00183	0.006	CcSEcCtD
Trihexyphenidyl—Paranoia—Topiramate—obesity	0.00181	0.00594	CcSEcCtD
Trihexyphenidyl—Vision blurred—Diethylpropion—obesity	0.0018	0.00591	CcSEcCtD
Trihexyphenidyl—Agitation—Diethylpropion—obesity	0.00176	0.00576	CcSEcCtD
Trihexyphenidyl—Tachycardia—Phentermine—obesity	0.00175	0.00574	CcSEcCtD
Trihexyphenidyl—Delusion—Topiramate—obesity	0.00174	0.00572	CcSEcCtD
Trihexyphenidyl—Hyperkinesia—Bupropion—obesity	0.00169	0.00554	CcSEcCtD
Trihexyphenidyl—Agitation—Cimetidine—obesity	0.00167	0.00548	CcSEcCtD
Trihexyphenidyl—Somnolence—Phenylpropanolamine—obesity	0.00166	0.00547	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Bupropion—obesity	0.00166	0.00546	CcSEcCtD
Trihexyphenidyl—Dizziness—Methamphetamine—obesity	0.00165	0.00541	CcSEcCtD
Trihexyphenidyl—Constipation—Phenylpropanolamine—obesity	0.0016	0.00526	CcSEcCtD
Trihexyphenidyl—Dizziness—Benzphetamine—obesity	0.00159	0.00522	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Sibutramine—obesity	0.00157	0.00517	CcSEcCtD
Trihexyphenidyl—Memory impairment—Topiramate—obesity	0.00157	0.00516	CcSEcCtD
Trihexyphenidyl—Headache—Methamphetamine—obesity	0.00156	0.00513	CcSEcCtD
Trihexyphenidyl—Mydriasis—Topiramate—obesity	0.00155	0.00508	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Phenylpropanolamine—obesity	0.00154	0.00507	CcSEcCtD
Trihexyphenidyl—Constipation—Phentermine—obesity	0.00153	0.00503	CcSEcCtD
Trihexyphenidyl—Dry skin—Orlistat—obesity	0.00153	0.00501	CcSEcCtD
Trihexyphenidyl—Tachycardia—Diethylpropion—obesity	0.00152	0.00499	CcSEcCtD
Trihexyphenidyl—Headache—Benzphetamine—obesity	0.00151	0.00495	CcSEcCtD
Trihexyphenidyl—Confusional state—Cimetidine—obesity	0.0015	0.00491	CcSEcCtD
Trihexyphenidyl—Dry skin—Sibutramine—obesity	0.00148	0.00485	CcSEcCtD
Trihexyphenidyl—Dizziness—Phendimetrazine—obesity	0.00145	0.00476	CcSEcCtD
Trihexyphenidyl—Tachycardia—Cimetidine—obesity	0.00145	0.00475	CcSEcCtD
Trihexyphenidyl—Nausea—Benzphetamine—obesity	0.00143	0.00469	CcSEcCtD
Trihexyphenidyl—Somnolence—Diethylpropion—obesity	0.00139	0.00455	CcSEcCtD
Trihexyphenidyl—Headache—Phendimetrazine—obesity	0.00137	0.00451	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Bupropion—obesity	0.00137	0.00451	CcSEcCtD
Trihexyphenidyl—Constipation—Diethylpropion—obesity	0.00133	0.00438	CcSEcCtD
Trihexyphenidyl—Somnolence—Cimetidine—obesity	0.00132	0.00433	CcSEcCtD
Trihexyphenidyl—Nausea—Phendimetrazine—obesity	0.0013	0.00427	CcSEcCtD
Trihexyphenidyl—Dry skin—Bupropion—obesity	0.00129	0.00423	CcSEcCtD
Trihexyphenidyl—Asthenia—Phentermine—obesity	0.00129	0.00422	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Diethylpropion—obesity	0.00128	0.00422	CcSEcCtD
Trihexyphenidyl—Constipation—Cimetidine—obesity	0.00127	0.00416	CcSEcCtD
Trihexyphenidyl—Dizziness—Phenylpropanolamine—obesity	0.00124	0.00407	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Cimetidine—obesity	0.00122	0.00401	CcSEcCtD
Trihexyphenidyl—Vomiting—Phenylpropanolamine—obesity	0.00119	0.00391	CcSEcCtD
Trihexyphenidyl—Dizziness—Phentermine—obesity	0.00119	0.00389	CcSEcCtD
Trihexyphenidyl—Rash—Phenylpropanolamine—obesity	0.00118	0.00388	CcSEcCtD
Trihexyphenidyl—Dermatitis—Phenylpropanolamine—obesity	0.00118	0.00387	CcSEcCtD
Trihexyphenidyl—Vomiting—Phentermine—obesity	0.00114	0.00374	CcSEcCtD
Trihexyphenidyl—Rash—Phentermine—obesity	0.00113	0.00371	CcSEcCtD
Trihexyphenidyl—Dermatitis—Phentermine—obesity	0.00113	0.00371	CcSEcCtD
Trihexyphenidyl—Headache—Phentermine—obesity	0.00112	0.00369	CcSEcCtD
Trihexyphenidyl—Nausea—Phenylpropanolamine—obesity	0.00111	0.00365	CcSEcCtD
Trihexyphenidyl—Weight decreased—Bupropion—obesity	0.0011	0.00361	CcSEcCtD
Trihexyphenidyl—Hyperkinesia—Topiramate—obesity	0.00108	0.00353	CcSEcCtD
Trihexyphenidyl—Nausea—Phentermine—obesity	0.00106	0.00349	CcSEcCtD
Trihexyphenidyl—Asthenia—Cimetidine—obesity	0.00106	0.00349	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Topiramate—obesity	0.00106	0.00348	CcSEcCtD
Trihexyphenidyl—Dizziness—Diethylpropion—obesity	0.00103	0.00338	CcSEcCtD
Trihexyphenidyl—Vomiting—Diethylpropion—obesity	0.000991	0.00325	CcSEcCtD
Trihexyphenidyl—Rash—Diethylpropion—obesity	0.000983	0.00323	CcSEcCtD
Trihexyphenidyl—Dermatitis—Diethylpropion—obesity	0.000982	0.00322	CcSEcCtD
Trihexyphenidyl—Dizziness—Cimetidine—obesity	0.000981	0.00322	CcSEcCtD
Trihexyphenidyl—Headache—Diethylpropion—obesity	0.000977	0.00321	CcSEcCtD
Trihexyphenidyl—Hallucination—Bupropion—obesity	0.000968	0.00318	CcSEcCtD
Trihexyphenidyl—Tension—Sibutramine—obesity	0.000953	0.00313	CcSEcCtD
Trihexyphenidyl—Vision blurred—Orlistat—obesity	0.000946	0.0031	CcSEcCtD
Trihexyphenidyl—Nervousness—Sibutramine—obesity	0.000943	0.0031	CcSEcCtD
Trihexyphenidyl—Vomiting—Cimetidine—obesity	0.000943	0.0031	CcSEcCtD
Trihexyphenidyl—Rash—Cimetidine—obesity	0.000935	0.00307	CcSEcCtD
Trihexyphenidyl—Dermatitis—Cimetidine—obesity	0.000934	0.00307	CcSEcCtD
Trihexyphenidyl—Headache—Cimetidine—obesity	0.000929	0.00305	CcSEcCtD
Trihexyphenidyl—Nausea—Diethylpropion—obesity	0.000926	0.00304	CcSEcCtD
Trihexyphenidyl—Vision blurred—Sibutramine—obesity	0.000915	0.003	CcSEcCtD
Trihexyphenidyl—Agitation—Sibutramine—obesity	0.000892	0.00293	CcSEcCtD
Trihexyphenidyl—Nausea—Cimetidine—obesity	0.000881	0.00289	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Topiramate—obesity	0.000875	0.00287	CcSEcCtD
Trihexyphenidyl—Tension—Bupropion—obesity	0.000831	0.00273	CcSEcCtD
Trihexyphenidyl—Nervousness—Bupropion—obesity	0.000822	0.0027	CcSEcCtD
Trihexyphenidyl—Confusional state—Sibutramine—obesity	0.000799	0.00262	CcSEcCtD
Trihexyphenidyl—Vision blurred—Bupropion—obesity	0.000798	0.00262	CcSEcCtD
Trihexyphenidyl—Agitation—Bupropion—obesity	0.000778	0.00255	CcSEcCtD
Trihexyphenidyl—Tachycardia—Sibutramine—obesity	0.000774	0.00254	CcSEcCtD
Trihexyphenidyl—Somnolence—Sibutramine—obesity	0.000705	0.00231	CcSEcCtD
Trihexyphenidyl—Weight decreased—Topiramate—obesity	0.0007	0.0023	CcSEcCtD
Trihexyphenidyl—Confusional state—Bupropion—obesity	0.000697	0.00229	CcSEcCtD
Trihexyphenidyl—Constipation—Sibutramine—obesity	0.000678	0.00222	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Orlistat—obesity	0.000675	0.00222	CcSEcCtD
Trihexyphenidyl—Tachycardia—Bupropion—obesity	0.000674	0.00221	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Sibutramine—obesity	0.000653	0.00214	CcSEcCtD
Trihexyphenidyl—Hallucination—Topiramate—obesity	0.000616	0.00202	CcSEcCtD
Trihexyphenidyl—Somnolence—Bupropion—obesity	0.000614	0.00202	CcSEcCtD
Trihexyphenidyl—Constipation—Bupropion—obesity	0.000591	0.00194	CcSEcCtD
Trihexyphenidyl—Asthenia—Orlistat—obesity	0.000588	0.00193	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Bupropion—obesity	0.000569	0.00187	CcSEcCtD
Trihexyphenidyl—Asthenia—Sibutramine—obesity	0.000569	0.00187	CcSEcCtD
Trihexyphenidyl—Dizziness—Orlistat—obesity	0.000542	0.00178	CcSEcCtD
Trihexyphenidyl—Tension—Topiramate—obesity	0.000529	0.00174	CcSEcCtD
Trihexyphenidyl—Dizziness—Sibutramine—obesity	0.000524	0.00172	CcSEcCtD
Trihexyphenidyl—Nervousness—Topiramate—obesity	0.000524	0.00172	CcSEcCtD
Trihexyphenidyl—Vomiting—Orlistat—obesity	0.000521	0.00171	CcSEcCtD
Trihexyphenidyl—Rash—Orlistat—obesity	0.000516	0.0017	CcSEcCtD
Trihexyphenidyl—Dermatitis—Orlistat—obesity	0.000516	0.00169	CcSEcCtD
Trihexyphenidyl—Headache—Orlistat—obesity	0.000513	0.00168	CcSEcCtD
Trihexyphenidyl—Vision blurred—Topiramate—obesity	0.000508	0.00167	CcSEcCtD
Trihexyphenidyl—Vomiting—Sibutramine—obesity	0.000504	0.00165	CcSEcCtD
Trihexyphenidyl—Rash—Sibutramine—obesity	0.0005	0.00164	CcSEcCtD
Trihexyphenidyl—Dermatitis—Sibutramine—obesity	0.000499	0.00164	CcSEcCtD
Trihexyphenidyl—Headache—Sibutramine—obesity	0.000497	0.00163	CcSEcCtD
Trihexyphenidyl—Asthenia—Bupropion—obesity	0.000496	0.00163	CcSEcCtD
Trihexyphenidyl—Agitation—Topiramate—obesity	0.000496	0.00163	CcSEcCtD
Trihexyphenidyl—Nausea—Orlistat—obesity	0.000486	0.0016	CcSEcCtD
Trihexyphenidyl—Nausea—Sibutramine—obesity	0.000471	0.00155	CcSEcCtD
Trihexyphenidyl—Dizziness—Bupropion—obesity	0.000457	0.0015	CcSEcCtD
Trihexyphenidyl—Confusional state—Topiramate—obesity	0.000444	0.00146	CcSEcCtD
Trihexyphenidyl—Vomiting—Bupropion—obesity	0.000439	0.00144	CcSEcCtD
Trihexyphenidyl—Rash—Bupropion—obesity	0.000436	0.00143	CcSEcCtD
Trihexyphenidyl—Dermatitis—Bupropion—obesity	0.000435	0.00143	CcSEcCtD
Trihexyphenidyl—Headache—Bupropion—obesity	0.000433	0.00142	CcSEcCtD
Trihexyphenidyl—Tachycardia—Topiramate—obesity	0.00043	0.00141	CcSEcCtD
Trihexyphenidyl—Nausea—Bupropion—obesity	0.00041	0.00135	CcSEcCtD
Trihexyphenidyl—Somnolence—Topiramate—obesity	0.000391	0.00128	CcSEcCtD
Trihexyphenidyl—Constipation—Topiramate—obesity	0.000376	0.00124	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Topiramate—obesity	0.000363	0.00119	CcSEcCtD
Trihexyphenidyl—Asthenia—Topiramate—obesity	0.000316	0.00104	CcSEcCtD
Trihexyphenidyl—Dizziness—Topiramate—obesity	0.000291	0.000956	CcSEcCtD
Trihexyphenidyl—Vomiting—Topiramate—obesity	0.00028	0.000919	CcSEcCtD
Trihexyphenidyl—Rash—Topiramate—obesity	0.000278	0.000911	CcSEcCtD
Trihexyphenidyl—Dermatitis—Topiramate—obesity	0.000277	0.00091	CcSEcCtD
Trihexyphenidyl—Headache—Topiramate—obesity	0.000276	0.000905	CcSEcCtD
Trihexyphenidyl—Nausea—Topiramate—obesity	0.000261	0.000858	CcSEcCtD
Trihexyphenidyl—CHRM5—Signaling Pathways—ESR1—obesity	1.53e-05	6.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SOCS1—obesity	1.53e-05	6.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CD36—obesity	1.52e-05	6.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SOCS1—obesity	1.52e-05	6.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PIK3CD—obesity	1.51e-05	6.24e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PRKCB—obesity	1.51e-05	6.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—F2—obesity	1.51e-05	6.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PIK3CD—obesity	1.51e-05	6.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SOCS3—obesity	1.51e-05	6.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CG—obesity	1.51e-05	6.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SOCS1—obesity	1.51e-05	6.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SOCS3—obesity	1.5e-05	6.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PIK3CD—obesity	1.49e-05	6.16e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—BAD—obesity	1.49e-05	6.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IRS1—obesity	1.49e-05	6.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SOCS3—obesity	1.49e-05	6.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—GNB3—obesity	1.48e-05	6.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—GNB3—obesity	1.47e-05	6.07e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—GNB3—obesity	1.46e-05	6.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—TYK2—obesity	1.46e-05	6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—PIK3CB—obesity	1.45e-05	5.99e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—TYK2—obesity	1.45e-05	5.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IGF2—obesity	1.45e-05	5.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—PIK3CB—obesity	1.45e-05	5.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IGF2—obesity	1.45e-05	5.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CG—obesity	1.45e-05	5.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—RHOA—obesity	1.44e-05	5.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—MTHFR—obesity	1.44e-05	5.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—RHOA—obesity	1.44e-05	5.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—GNAS—obesity	1.44e-05	5.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—TYK2—obesity	1.44e-05	5.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—POMC—obesity	1.44e-05	5.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—PIK3CB—obesity	1.43e-05	5.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—GNAS—obesity	1.43e-05	5.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IGF2—obesity	1.43e-05	5.9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PIK3R1—obesity	1.43e-05	5.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—INS—obesity	1.43e-05	5.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IRS1—obesity	1.43e-05	5.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—RHOA—obesity	1.43e-05	5.88e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PIK3R1—obesity	1.43e-05	5.87e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—GNAS—obesity	1.42e-05	5.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PPARA—obesity	1.42e-05	5.84e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PIK3R1—obesity	1.41e-05	5.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—APOB—obesity	1.41e-05	5.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCL2—obesity	1.41e-05	5.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—APOB—obesity	1.4e-05	5.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—APOB—obesity	1.39e-05	5.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IGF1—obesity	1.38e-05	5.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AKT2—obesity	1.38e-05	5.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—POMC—obesity	1.38e-05	5.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCL5—obesity	1.38e-05	5.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—AGT—obesity	1.37e-05	5.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCL5—obesity	1.37e-05	5.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—INS—obesity	1.37e-05	5.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCL5—obesity	1.36e-05	5.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCL2—obesity	1.35e-05	5.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LPL—obesity	1.35e-05	5.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—APOE—obesity	1.34e-05	5.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LPL—obesity	1.34e-05	5.53e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FOXO1—obesity	1.34e-05	5.5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—RPS6KB1—obesity	1.33e-05	5.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CAV1—obesity	1.33e-05	5.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FOXO1—obesity	1.33e-05	5.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—RPS6KB1—obesity	1.33e-05	5.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—APOA1—obesity	1.33e-05	5.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LPL—obesity	1.33e-05	5.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CD—obesity	1.33e-05	5.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IGF1—obesity	1.32e-05	5.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AKT2—obesity	1.32e-05	5.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PIK3CB—obesity	1.32e-05	5.44e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FOXO1—obesity	1.32e-05	5.43e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—RPS6KB1—obesity	1.32e-05	5.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PIK3CB—obesity	1.32e-05	5.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—PIK3CA—obesity	1.31e-05	5.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—SERPINE1—obesity	1.31e-05	5.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PIK3CB—obesity	1.3e-05	5.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TYK2—obesity	1.28e-05	5.26e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CD—obesity	1.27e-05	5.24e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—RHOA—obesity	1.27e-05	5.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—PIK3CA—obesity	1.26e-05	5.19e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—SERPINE1—obesity	1.26e-05	5.18e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3R1—obesity	1.25e-05	5.16e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—NOS3—obesity	1.25e-05	5.16e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PRKCD—obesity	1.24e-05	5.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PRKCD—obesity	1.24e-05	5.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PRKCD—obesity	1.22e-05	5.04e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TYK2—obesity	1.22e-05	5.04e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CG—obesity	1.21e-05	5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—HTR2A—obesity	1.21e-05	5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—RHOA—obesity	1.21e-05	5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—C3—obesity	1.21e-05	4.99e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—HTR2A—obesity	1.21e-05	4.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—C3—obesity	1.21e-05	4.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3R1—obesity	1.2e-05	4.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—NOS3—obesity	1.2e-05	4.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—HTR2A—obesity	1.2e-05	4.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—C3—obesity	1.2e-05	4.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—PIK3CA—obesity	1.19e-05	4.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PPARG—obesity	1.17e-05	4.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MTOR—obesity	1.16e-05	4.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CB—obesity	1.16e-05	4.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—POMC—obesity	1.15e-05	4.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IRS2—obesity	1.15e-05	4.75e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AGT—obesity	1.15e-05	4.74e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IRS2—obesity	1.15e-05	4.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—INS—obesity	1.15e-05	4.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AGT—obesity	1.15e-05	4.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—PIK3CA—obesity	1.14e-05	4.71e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IRS2—obesity	1.14e-05	4.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AGT—obesity	1.14e-05	4.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LEP—obesity	1.13e-05	4.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—APOE—obesity	1.13e-05	4.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—APOE—obesity	1.12e-05	4.63e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LEP—obesity	1.12e-05	4.63e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CAV1—obesity	1.12e-05	4.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—APOA1—obesity	1.11e-05	4.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CAV1—obesity	1.11e-05	4.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LEP—obesity	1.11e-05	4.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—APOE—obesity	1.11e-05	4.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—APOA1—obesity	1.11e-05	4.58e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MTOR—obesity	1.11e-05	4.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CB—obesity	1.11e-05	4.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CAV1—obesity	1.1e-05	4.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—APOA1—obesity	1.1e-05	4.53e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ESR1—obesity	1.08e-05	4.44e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—AKT1—obesity	1.07e-05	4.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ESR1—obesity	1.07e-05	4.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CD—obesity	1.07e-05	4.39e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—F2—obesity	1.06e-05	4.38e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PRKCB—obesity	1.06e-05	4.38e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ESR1—obesity	1.06e-05	4.38e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PRKCB—obesity	1.06e-05	4.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—F2—obesity	1.06e-05	4.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL6—obesity	1.06e-05	4.35e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ALB—obesity	1.05e-05	4.34e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—BAD—obesity	1.05e-05	4.33e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PRKCB—obesity	1.05e-05	4.33e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—F2—obesity	1.05e-05	4.33e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—BAD—obesity	1.05e-05	4.32e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—BAD—obesity	1.04e-05	4.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—AKT1—obesity	1.03e-05	4.24e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CG—obesity	1.02e-05	4.19e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CG—obesity	1.01e-05	4.18e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL6—obesity	1.01e-05	4.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3R1—obesity	1.01e-05	4.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—NOS3—obesity	1.01e-05	4.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IRS1—obesity	1.01e-05	4.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MMP9—obesity	1.01e-05	4.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CG—obesity	1e-05	4.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IRS1—obesity	1e-05	4.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IRS1—obesity	9.93e-06	4.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MAPK8—obesity	9.77e-06	4.03e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—AKT1—obesity	9.75e-06	4.02e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—POMC—obesity	9.69e-06	3.99e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—POMC—obesity	9.66e-06	3.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—INS—obesity	9.63e-06	3.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MMP9—obesity	9.63e-06	3.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—INS—obesity	9.6e-06	3.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—POMC—obesity	9.56e-06	3.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—INS—obesity	9.51e-06	3.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCL2—obesity	9.48e-06	3.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCL2—obesity	9.45e-06	3.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MAPK8—obesity	9.36e-06	3.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCL2—obesity	9.36e-06	3.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—AKT1—obesity	9.34e-06	3.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IGF1—obesity	9.32e-06	3.84e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKT2—obesity	9.31e-06	3.84e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CB—obesity	9.29e-06	3.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IGF1—obesity	9.29e-06	3.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKT2—obesity	9.28e-06	3.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PTGS2—obesity	9.21e-06	3.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IGF1—obesity	9.2e-06	3.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKT2—obesity	9.19e-06	3.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CD—obesity	8.95e-06	3.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—STAT3—obesity	8.94e-06	3.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CD—obesity	8.92e-06	3.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—PIK3CA—obesity	8.86e-06	3.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SERPINE1—obesity	8.85e-06	3.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—PIK3CA—obesity	8.83e-06	3.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CD—obesity	8.83e-06	3.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SERPINE1—obesity	8.82e-06	3.63e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—PIK3CA—obesity	8.75e-06	3.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SERPINE1—obesity	8.73e-06	3.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TYK2—obesity	8.61e-06	3.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TYK2—obesity	8.58e-06	3.53e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—STAT3—obesity	8.56e-06	3.53e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—RHOA—obesity	8.53e-06	3.52e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—RHOA—obesity	8.51e-06	3.51e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TYK2—obesity	8.49e-06	3.5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3R1—obesity	8.45e-06	3.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NOS3—obesity	8.45e-06	3.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—RHOA—obesity	8.43e-06	3.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3R1—obesity	8.42e-06	3.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NOS3—obesity	8.42e-06	3.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3R1—obesity	8.34e-06	3.44e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NOS3—obesity	8.34e-06	3.44e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MYC—obesity	8.3e-06	3.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TGFB1—obesity	8.28e-06	3.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PIK3CA—obesity	8.05e-06	3.32e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PIK3CA—obesity	8.02e-06	3.31e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MYC—obesity	7.95e-06	3.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PIK3CA—obesity	7.94e-06	3.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TGFB1—obesity	7.93e-06	3.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MTOR—obesity	7.8e-06	3.21e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CB—obesity	7.8e-06	3.21e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CB—obesity	7.77e-06	3.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MTOR—obesity	7.77e-06	3.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CB—obesity	7.7e-06	3.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MTOR—obesity	7.7e-06	3.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—AKT1—obesity	7.24e-06	2.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—AKT1—obesity	7.22e-06	2.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—AKT1—obesity	7.15e-06	2.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL6—obesity	7.12e-06	2.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL6—obesity	7.1e-06	2.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CA—obesity	7.05e-06	2.9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL6—obesity	7.03e-06	2.9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MMP9—obesity	6.78e-06	2.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MMP9—obesity	6.76e-06	2.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CA—obesity	6.75e-06	2.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MMP9—obesity	6.69e-06	2.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MAPK8—obesity	6.59e-06	2.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—AKT1—obesity	6.57e-06	2.71e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MAPK8—obesity	6.57e-06	2.71e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—AKT1—obesity	6.55e-06	2.7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MAPK8—obesity	6.51e-06	2.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—AKT1—obesity	6.49e-06	2.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL6—obesity	6.24e-06	2.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—STAT3—obesity	6.03e-06	2.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—STAT3—obesity	6.01e-06	2.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL6—obesity	5.98e-06	2.46e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—STAT3—obesity	5.95e-06	2.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AKT1—obesity	5.76e-06	2.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CA—obesity	5.67e-06	2.33e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MYC—obesity	5.6e-06	2.31e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TGFB1—obesity	5.59e-06	2.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MYC—obesity	5.58e-06	2.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TGFB1—obesity	5.57e-06	2.29e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MYC—obesity	5.53e-06	2.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AKT1—obesity	5.51e-06	2.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TGFB1—obesity	5.51e-06	2.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CA—obesity	4.75e-06	1.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CA—obesity	4.74e-06	1.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CA—obesity	4.69e-06	1.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—AKT1—obesity	4.63e-06	1.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6—obesity	4.21e-06	1.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6—obesity	4.2e-06	1.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6—obesity	4.15e-06	1.71e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKT1—obesity	3.88e-06	1.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKT1—obesity	3.87e-06	1.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKT1—obesity	3.83e-06	1.58e-05	CbGpPWpGaD
